Picture EasyFairs Connect in Pharma 2023 Geneva 650x89px
Organisation › Details

Resalis Therapeutics S.r.l.

Resalis Therapeutics’ transformative metabolic disease approach targets a master regulator of multiple pathways underlying obesity and fatty liver disease. The company is applying its profound understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of hepatic steatosis. Building on robust preclinical evidence, Resalis will rapidly bring RES-010 into clinical trials for a range of metabolic disorders. *


Period Start 2021-01-01 established
Product Industry RES-010 (Resalis Therapeutics, antisense oligonucleotide targeting miR-22)
  Street 52 Via Nizza
  City 10126 Torino (TO)
    Address record changed: 2023-03-05
Basic data Employees n. a.
    * Document for »About Section«: Resalis Therapeutics S.r.l.. (2/22/23). "Press Release: Resalis Therapeutics Announces Seed Financing of €10 Million to Fund Non-coding RNA-based Therapeutics for Metabolic Diseases". Torino.
Record changed: 2023-03-05


Picture EasyFairs Connect in Pharma 2023 Geneva Speakers 650x200px

More documents for Resalis Therapeutics S.r.l.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group ASCO 2023 Annual Meeting Connecting Cancer 650x300px

» top